Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

What symbol and exchange does Cerenome shares trade?

Cerenome trades on the NASDAQ stock market under the symbol CNSY.

What is Cerenome stock price doing today?

As of October 29, 2026, CNSY stock price was flat at $1.74 with 38,402 million shares trading.

How much is Cerenome worth?

CNSY has a market cap of $13.21 million. This is considered a Sub-Micro Cap stock.

How much money does Cerenome make?

Last quarter Cerenome reported $411,000 in Revenue and -$1.31 earnings per share. This fell short of revenue expectation by $-687,000 and missed earnings estimates by -$.41.

What are the top ETFs holding Cerenome?

The top ETF exchange traded funds that CNSY belongs to (by Net Assets): VTI, VXF, IWC.

What are the support and resistance levels for Cerenome (CNSY)?

CNSY support price is $1.61 and resistance is $1.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNSY shares will trade within this expected range on the day.